Effect of hCG on Receptivity of the Human Endometrium
Infertility, Subfertility
About this trial
This is an interventional basic science trial for Infertility focused on measuring embryo, implantation, blastocyst, in vitro fertilization, human chorionic gonadotropin
Eligibility Criteria
Inclusion Criteria:
- between the ages of 18-34 years old
- successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525)
- meet the ASRM criteria for oocyte donation
Exclusion Criteria:
- younger than 18 years old or older than 34 years old
- have not successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525)
- do not meet the ASRM criteria for oocyte donation
Sites / Locations
- The Fertility Center , 3230 Eagle Park Drive NE, suite 100
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Drug: human chorionic gonadotropin (hCG)
IVF media ("Global"-trademark)
Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media ("Global"-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.